Dulaglutide Evidence Guide
Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing.
Our Take
Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing.
- Best for
- Type 2 diabetes management, cardiovascular risk reduction, once-weekly GLP-1 agonism
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 0.75mg subcutaneous once weekly, titrated to 1.5mg
Benefits and Evidence
- Glycemic Control: Level A, includes human evidence - HbA1c reductions of 0.8-1.6% across the AWARD Phase 3 trial program, with efficacy comparable to liraglutide and superior to exenatide extended-release.
- Cardiovascular Risk Reduction: Level A, includes human evidence - REWIND trial demonstrated 12% reduction in MACE (HR 0.88) in a broad population including patients without established cardiovascular disease - unique among GLP-1 agonist CVOTs.
- Body Weight Reduction: Level A, includes human evidence - Mean weight loss of 2-5 kg observed across AWARD trials, dose-dependent and sustained over treatment duration.
Side Effects and Warnings
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
- Fatigue
- Injection site reactions
- Boxed warning: Thyroid C-cell tumor risk in rodents
Research Dosage References
- <strong>Subcutaneous injection</strong> - 0.75 mg - Once weekly - Starting dose. Can be administered at any time of day with or without meals. Available as a pre-filled, single-dose pen.
- <strong>Subcutaneous injection</strong> - 1.5 mg or 3.0 mg or 4.5 mg - Once weekly - Dose may be increased for additional glycemic control. The 3.0 mg and 4.5 mg doses were approved in 2020 for enhanced efficacy.
Mechanism of Action
Dulaglutide activates the GLP-1 receptor through a GLP-1 analog moiety that has approximately 90% homology to native human GLP-1. The analog is fused to a modified human IgG4 Fc fragment, which serves multiple purposes: it protects the peptide from DPP-4 degradation, reduces renal clearance due to its large size, and enables FcRn-mediated recycling that extends the circulating half-life. GLP-1 receptor activation on pancreatic beta cells enhances glucose-dependent insulin secretion through cAMP-mediated signaling. On alpha cells, it suppresses glucagon secretion during hyperglycemia. In the gastrointestinal tract, it delays gastric emptying, and in the central nervous system, it promotes satiety and reduces food intake. The cardiovascular benefits observed in REWIND are believed to be mediated through multiple mechanisms including improved endothelial function, reduced inflammation, decreased oxidative stress, and direct effects on cardiomyocytes expressing GLP-1 receptors.
Legal Status
FDA approved (2014). Prescription required. Not a controlled substance.
Primary Sources
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 2019.
- Efficacy and safety of dulaglutide versus exenatide once weekly (AWARD-1). Diabetes Care, 2014.
- Dulaglutide versus insulin glargine in type 2 diabetes (AWARD-2). The Lancet Diabetes & Endocrinology, 2015.